Using low dose colchicine to reduce vascular risks in patients with peripheral artery disease
1/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10982432
This study is looking at whether a low dose of colchicine can help people with peripheral artery disease (PAD) by reducing the risk of heart problems, and we're inviting 1,000 participants from the U.S. to join us in this friendly trial where some will take the medication and others will take a placebo, all while we keep a close eye on their health.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10982432 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of low dose colchicine on patients with peripheral artery disease (PAD) through a randomized, double-blind, placebo-controlled trial. The study aims to enroll 1,000 participants from the U.S. as part of a larger multinational effort to determine if this anti-inflammatory medication can lower the risk of cardiovascular events and complications related to PAD. Participants will receive either colchicine or a placebo daily, and their health outcomes will be closely monitored over the trial period. The research is led by a team of experienced investigators from Duke University, ensuring a robust approach to data collection and analysis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with peripheral artery disease who are at risk for cardiovascular events.
Not a fit: Patients who do not have peripheral artery disease or those who are not at risk for cardiovascular complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of heart attacks, strokes, and other serious complications for patients with peripheral artery disease.
How similar studies have performed: Previous studies have shown that colchicine can reduce cardiovascular risks in patients with coronary disease, indicating potential for success in this novel application for PAD.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PATEL, MANESH R — DUKE UNIVERSITY
- Study coordinator: PATEL, MANESH R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease